SCHEMBL4771500

SCHEMBL4771500

COc1ccnc(-c2cc3ccccc3c(Cl)n2)c1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCR1 P32246 1/20 0.57
CCR5 P51681 1/20 0.57
CCR8 P51685 1/20 0.57
ADORA3 P0DMS8 3/20 0.45
NPC1 O15118 3/20 0.40
RAB9A P51151 3/20 0.40
NOS3 P29474 1/20 0.39
NOS1 P29475 1/20 0.39
NOS2 P35228 1/20 0.39
TUBB4A P04350 1/20 0.39
TUBB P07437 1/20 0.39
TUBA3C P0DPH7 1/20 0.39
TUBA1B P68363 1/20 0.39
TUBA4A P68366 1/20 0.39
TUBB4B P68371 1/20 0.39
TUBB3 Q13509 1/20 0.39
TUBB2A Q13885 1/20 0.39
TUBB8 Q3ZCM7 1/20 0.39
TUBA3E Q6PEY2 1/20 0.39
TUBA1A Q71U36 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1536634 0.79 CCR1 (0.47) CCR1CCR5CCR8ADORA3NPC1
SCHEMBL4769223 0.78 CYP1A2 (0.48) ADORA3RAB9ACYP1A2DYRK1ACYP3A4
SCHEMBL4772286 0.78 CASP3 (0.48) ADORA3NPC1RAB9ACYP1A2CYP2A6
SCHEMBL4763954 0.78 NPC1 (0.58) ADORA3NPC1RAB9ASYKLMNA
SCHEMBL4766375 0.77 CCR1 (0.59) CCR1CCR5CCR8ADORA3NPC1
SCHEMBL4765203 0.76 MEN1 (0.55) ADORA3NPC1RAB9ACYP1A2CYP2A6
SCHEMBL4774988 0.76 CYP2D6 (0.53) ADORA3NPC1CYP17A1CYP11B1CYP11B2
SCHEMBL196913 0.76 CCR1 (0.83) CCR1CCR5CCR8NPC1RAB9A
SCHEMBL182529 0.76 CCR1 (1.00) CCR1CCR5CCR8NPC1RAB9A
SCHEMBL29395249 0.76 CCR1 (1.00) CCR1CCR5CCR8NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1020445-B1 FUSED PYRIDINE DERIVATIVES EISAI R&D MAN CO LTD (JP) 2008-08-13 EP disclosed
US-6875761-B2 Certain 1,3-disubstituted isoquinoline derivatives EISAI CO., LTD. (JP) 2005-04-05 US disclosed
US-20040204421-A1 Certain 1,3-disubstituted isoquinoline derivatives EISAI CO., LTD. 2004-10-14 US disclosed
US-6790844-B2 MUSCLE RELAXANTS; ANTISEROTONINE AGENT EISAI CO., LTD (JP) 2004-09-14 US disclosed
US-20020013460-A1 Condensed pyridine compound EISAI CO., LTD 2002-01-31 US disclosed
US-6340759-B1 ANTISPASMODIC AGENTS EISAI CO., LTD. (JP) 2002-01-22 US disclosed
EP-1020445-A1 FUSED PYRIDINE DERIVATIVES Eisai Co., Ltd. (JP) 2000-07-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020013460-A1 Condensed pyridine compound MUSK, HTR1A, PAX3 CCR1 2893/4885CCR5 2731/4885CCR8 4451/4885
US-20040204421-A1 Certain 1,3-disubstituted isoquinoline derivatives MUSK, HTR1A, RYR1 CCR1 2141/4885CCR5 2604/4885CCR8 4584/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.